KinDex Pharmaceutical, a Seattle, WA-based biotechnology company, raised $5m in Series A funding.
Backers included Polaris Partners.
The company intends to use the funds to initiate the planned Phase 2 trial of their most advanced candidate, KDT501, in Type 2 diabetic patients as well as undertake additional preclinical and mechanistic studies in brown fat biology.
Led by Jeffrey Bland, Ph.D., CEO, KinDex Pharmaceuticals was formed, in parellel with the investment, by the reorganization of KinDex Therapeutics, LLC, to focus on discovering and developing molecules that modulate key regulatory networks associated with obesity, inflammation and chronic disease.
FinSMEs
25/03/2014